Ramalingam Ratnasabapathy, MD
Hematology & Oncology · Henderson, NVNPI 1144220781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,871 of the $25,079 with a category attached, or 71.3%. It is spread thinly across 59 manufacturers, the largest accounting for just 11.1%.
Across 736 payments — averaging $34.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3K
- Daiichi Sankyo Inc.$3K
- AstraZeneca$2K
- Genentech USA, Inc.$2K
- Novartis$2K
- Bayer$1K
- plus $12K from 53 others
Across 55 payments — averaging $2477.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$113K
- Beone Medicines USA, Inc.$15K
- Exelixis Inc.$8K
- AstraZeneca$413
What the payments were for
- Consulting fees$4,54518%
- Food & beverage$17,87171%
- Education$1,5776%
- Gifts$2051%
- Other$8814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,079 in reported general payments places this provider in the 70th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 22 | $389,463 |
| Lenalidomide | 17 | $250,556 |
| NplateRomiplostim | 12 | $242,116 |
| Somatuline DepotLanreotide Acetate | 13 | $232,678 |
| ImbruvicaIbrutinib | 12 | $199,621 |
| KisqaliRibociclib Succinate | 12 | $197,167 |
| VenclextaVenetoclax | 11 | $162,559 |
| EliquisApixaban | 67 | $71,292 |
| Abiraterone Acetate | 19 | $44,741 |
| XareltoRivaroxaban | 23 | $12,100 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $1,655 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,335 |
| Letrozole | 55 | $1,149 |
| Gabapentin | 45 | $958 |
| Hydrocortisone | 24 | $789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $489 | $389,46322 claims |
| AmgenNplate | $258 | $242,11612 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $284 | $232,67813 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $74 | $199,62112 claims |
| NovartisKisqali | $2,329 | $197,16712 claims |
| AbbVieVenclexta | $210 | $162,55911 claims |
| PfizerEliquis | $586 | $71,29267 claims |
| Johnson & JohnsonXarelto | $751 | $12,10023 claims |
| Lilly USA, LLCOlanzapine | $318 | $30225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Henderson
- Anthony NguyenHenderson$210K
- Russell GollardHenderson$105K
- Rupesh ParikhHenderson$67K
- Stephani ChristensenHenderson$10K
- Resty TibayanHenderson$10K
- Nutan ParikhHenderson$10K
- Muhammad GhaniHenderson$9K
- Khoi DaoHenderson$8K
- Gilbert NyamuswaHenderson$4K
- Nicholas VogelzangLas Vegas$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.